NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
Industry Trends
Kymera Strikes License Agreement Deals With Sanofi, Gilead
Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
South Korea’s Drug Pricing Reforms Reshape Market Access Landscape
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
NICE Expands TAVI Guidance for Aortic Valve Regurgitation
Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and … Read more
NICE Guidance Catalyzes Digital Mental Health Innovation
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.